Bayer (BAYRY)
(Delayed Data from OTC)
$7.81 USD
+0.01 (0.13%)
Updated May 10, 2024 03:59 PM ET
3-Hold of 5 3
B Value A Growth F Momentum B VGM
Price, Consensus and EPS Surprise
BAYRY 7.81 +0.01(0.13%)
Will BAYRY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BAYRY
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Other News for BAYRY
Bayer to present data from Kerendia trial program at Heart Failure 2024 Congress
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
AI-discovered drugs have an 80%–90% success rate: study
Elanco surges on Q1 beat, anticipated product launches
Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks